iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$9.55 USD
+0.13 (1.38%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $9.54 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.55 USD
+0.13 (1.38%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $9.54 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -62.42% and -68.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
by Zacks Equity Research
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug
by Zacks Equity Research
Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.